Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients
Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients
复制标题
头颈癌患者血清西妥昔单抗和EGFR相关标志物与皮肤疾病的相关性
DOI：
10.1007/s00280-020-04228-4
复制
发表时间：
2021
影响因子：
3
通讯作者：
Kawakami Junichi
中科院分区：
文献类型：
--
作者：
Shibata Kaito;Naito Takafumi;Hirakawa Satoshi;Suzuki Koji;Hosokawa Seiji;Mineta Hiroyuki;Kawakami Junichi
目的西妥昔单抗抑制癌细胞和皮肤细胞的表皮生长因子受体(EGFR)信号转导，从而产生抗癌和皮肤病的作用。本研究旨在评价头颈部肿瘤患者血清西妥昔单抗与表皮生长因子受体相关标志物及不良反应的关系。方法34例头颈部肿瘤患者每周静脉注射西妥昔单抗。西妥昔单抗的血药浓度在给药前测定。采血检测血清中可溶性表皮生长因子受体(SEGFR)和白介素6(IL-6)水平。结果西妥昔单抗和sEGFR水平分别与IL-6水平呈负相关和正相关。2~3级皮疹患者的血清西妥昔单抗水平是0~1级皮疹患者的2倍。与重度皮疹相关的血清西妥昔单抗临界值为71μg/m L(敏感性59%，特异性94%)。使用强的局部皮质类固醇治疗皮疹也与较高的血清西妥昔单抗水平相关。血清sEGFR和IL-6水平与皮肤病严重程度及用药无关。静脉注射硫酸镁治疗低镁血症与血清西妥昔单抗及EGFR相关指标无关。结论血清IL-6水平高的头颈部肿瘤患者血清西妥昔单抗水平往往较低。在研究人群中，血清西妥昔单抗与皮疹严重程度及其用药呈正相关。
PurposeCetuximab inhibits epidermal growth factor receptor (EGFR) signaling in cancer and skin cells, thereby inducing anti-cancer effects and skin disorders. The present study aimed to evaluate the relationships between serum cetuximab and EGFR-related markers, and adverse effects in head and neck cancer patients.MethodsThirty-four head and neck cancer patients receiving weekly intravenous cetuximab were enrolled. Serum cetuximab levels were determined just before dosing. Blood samples for determination of serum EGFR-related markers including soluble epidermal growth factor receptor (sEGFR) and interleukin-6 (IL-6) were obtained. The severities of skin disorders, their medications, and hypomagnesemia treatment were also assessed.ResultsSerum levels of cetuximab and sEGFR were negatively and positively correlated with that of IL-6, respectively. The serum cetuximab level was twofold higher in the patients with a grade 2–3 skin rash than with a grade 0–1 rash. The serum cetuximab cutoff value related to severe skin rash was 71 μg/mL (sensitivity, 59%; and specificity, 94%). The use of a strong topical corticosteroid for skin rash was also associated with a higher serum cetuximab level. Serum levels of sEGFR and IL-6 had no correlations with the skin disorder severities or their medications. Hypomagnesemia treatment using intravenous magnesium sulfate was not related to serum cetuximab and EGFR-related markers.ConclusionsHead and neck cancer patients with a higher serum IL-6 level tended to have a lower serum cetuximab level. Serum cetuximab had positive correlations to skin rash severity and its medication in the study population.